Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison.
Saved in:
| Title: | Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison. |
|---|---|
| Authors: | Dzienis M; Cancer Department, Gold Coast University Hospital, Southport, QLD, Australia., Mojebi A; Evidence Synthesis, Precision AQ, Vancouver, BC, Canada., Keeping S; Evidence Synthesis, Precision AQ, Vancouver, BC, Canada., Black CM; Value and Implementation, Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA., Giezek H; Biostatistics and Research Decision Sciences, Health Technology Assessment, MSD, Brussels, Belgium., Naicker N; Oncology European Clinical Development, MSD (UK) Limited, London, UK., Vanetta C; Biostatistics and Research Decision Sciences, Health Technology Assessment, MSD, Zurich, Switzerland., Park JE; Evidence Synthesis, Precision AQ, Vancouver, BC, Canada., Chan K; Evidence Synthesis, Precision AQ, Vancouver, BC, Canada., Merchant S; Value and Implementation, Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA., Zheng D; Value and Implementation, Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA. dandan.zheng@merck.com. |
| Source: | Advances in therapy [Adv Ther] 2025 Jun; Vol. 42 (6), pp. 2690-2707. Date of Electronic Publication: 2025 Apr 24. |
| Publication Type: | Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
